About aTyr Pharma (NASDAQ:LIFE)
aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
- Sub-Industry: Life Sciences Tools & Services
- Symbol: NASDAQ:LIFE
- CUSIP: 53217V10
- Web: www.atyrpharma.com/
Capitalization:- Market Cap: $128.73 million
- Outstanding Shares: 23,839,000
Average Prices:- 50 Day Moving Avg: $4.58
- 200 Day Moving Avg: $4.58
- 52 Week Range: $2.10 - $6.50
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.97
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $1.68 per share
- Price / Book: 3.21
Profitability:- EBITDA: ($50,670,000.00)
- Return on Equity: -107.31%
- Return on Assets: -76.55%
Debt:- Debt-to-Equity Ratio: 0.29%
- Current Ratio: 6.13%
- Quick Ratio: 6.13%
Misc:- Average Volume: 167,620 shs.
- Beta: 4.06
- Short Ratio: 13.67
Frequently Asked Questions for aTyr Pharma (NASDAQ:LIFE)
What is aTyr Pharma's stock symbol?
aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."
How were aTyr Pharma's earnings last quarter?
aTyr Pharma Inc (NASDAQ:LIFE) issued its quarterly earnings results on Monday, August, 14th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.57) by $0.06. View aTyr Pharma's Earnings History.
When will aTyr Pharma make its next earnings announcement?
Where is aTyr Pharma's stock going? Where will aTyr Pharma's stock price be in 2017?
4 analysts have issued 1 year price objectives for aTyr Pharma's stock. Their forecasts range from $2.85 to $7.00. On average, they anticipate aTyr Pharma's stock price to reach $4.46 in the next year. View Analyst Ratings for aTyr Pharma.
Who are some of aTyr Pharma's key competitors?
Some companies that are related to aTyr Pharma include Horizon Discovery Group PLC (HZD), Curis (CRIS), Chromadex Corp (CDXC), Compugen (CGEN), Nabriva Therapeutics AG (NBRV), Merrimack Pharmaceuticals (MACK), Pluristem Therapeutics (PSTI), Advaxis (ADXS), Silence Therapeutics plc (SLN), Organovo Holdings (ONVO), Organovo Holdings (ONVO), CASI Pharmaceuticals (CASI), Oramed Pharmaceuticals (ORMP), OncoMed Pharmaceuticals (OMED), Asterias Biotherapeutics (AST), Asterias Biotherapeutics (AST), Regulus Therapeutics (RGLS) and Infinity Pharmaceuticals (INFI).
Who are aTyr Pharma's key executives?
aTyr Pharma's management team includes the folowing people:
- John K. Clarke, Independent Chairman of the Board
- John D. Mendlein Ph.D., Chief Executive Officer, Director
- John T. Blake, Senior Vice President - Finance
- David John King Ph.D., Senior Vice President - Research
- Grove Matsuoka, Senior Vice President, Product Programs and Planning
- Ashraf Amanullah Ph.D., Vice President, Biologics Development and Manufacturing
- Sanuj K. Ravindran M.D., Chief Business Officer
- Sanjay S. Shukla M.D., Chief Medical Officer
- Timothy P. Coughlin CPA, Director
- Jeffrey S. Hatfield, Director
When did aTyr Pharma IPO?
(LIFE) raised $76 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Citigroup acted as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.
How do I buy aTyr Pharma stock?
Shares of aTyr Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is aTyr Pharma's stock price today?
One share of aTyr Pharma stock can currently be purchased for approximately $5.40.
MarketBeat Community Rating for aTyr Pharma (NASDAQ LIFE)MarketBeat's community ratings are surveys of what our community members think about aTyr Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for aTyr Pharma (NASDAQ:LIFE) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Hold Ratings, 1 Buy Rating |
| Consensus Rating: | Hold (Score: 2.25) |
| Consensus Price Target: | $4.46 (17.36% downside) |
Consensus Price Target History for aTyr Pharma (NASDAQ:LIFE)
Analysts' Ratings History for aTyr Pharma (NASDAQ:LIFE)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/7/2017 | Piper Jaffray Companies | Initiated Coverage | Overweight -> Overweight | $7.00 | High |  |
| 8/15/2017 | BMO Capital Markets | Set Price Target | Hold | $4.00 | High | |
| 3/20/2017 | Citigroup Inc. | Boost Price Target | Neutral | $3.00 -> $4.00 | Medium | |
| 3/18/2017 | J P Morgan Chase & Co | Reiterated Rating | Hold | | Medium | |
| 3/31/2016 | William Blair | Downgrade | Outperform -> Market Perform | | N/A | |
(Data available from 10/17/2015 forward)
Earnings History for aTyr Pharma (NASDAQ:LIFE)Earnings History by Quarter for aTyr Pharma (NASDAQ LIFE)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/13/2017 | | | | | | | N/A | |
| 8/14/2017 | Q2 2017 | ($0.57) | ($0.51) | | | View | N/A | |
| 5/11/2017 | Q1 2017 | ($0.50) | ($0.56) | | | View | N/A | |
| 11/14/2016 | Q3 2016 | ($0.67) | ($0.58) | | | View | N/A | |
| 8/10/2016 | Q216 | ($0.71) | ($0.65) | | | View | N/A | |
| 5/11/2016 | Q1 | ($0.70) | ($0.68) | | | View | N/A | |
| 3/30/2016 | Q4 | ($0.52) | ($0.70) | | | View | N/A | |
| 11/10/2015 | Q3 | ($0.48) | ($0.48) | | | View | N/A | |
| 8/12/2015 | Q215 | ($0.53) | ($0.74) | | | View | N/A | |
| 6/18/2015 | Q115 | ($0.41) | ($0.38) | | | View | N/A | |
| 11/5/2013 | Q313 | $0.97 | $1.02 | $926.10 million | $936.00 million | View | N/A | |
| 7/31/2013 | Q2 2013 | $0.96 | $0.72 | $952.06 million | $944.00 million | View | N/A | |
| 5/2/2013 | Q1 2013 | $1.04 | $1.07 | $958.56 million | $963.00 million | View | N/A | |
| 2/4/2013 | Q4 2012 | $1.11 | $1.11 | $988.85 million | $998.90 million | View | N/A | |
| 11/1/2012 | Q312 | $0.89 | $0.92 | $907.91 million | $911.00 million | View | N/A | |
| 7/31/2012 | | $0.97 | $0.96 | | | View | N/A | |
| 2/7/2012 | | $1.04 | $1.06 | | | View | N/A | |
| 10/25/2011 | | $0.88 | $0.94 | | | View | N/A | |
| 7/28/2011 | | $0.95 | $0.89 | | | View | N/A | |
| 4/26/2011 | | $0.85 | $0.85 | | | View | N/A | |
| 2/3/2011 | | $0.87 | $0.90 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for aTyr Pharma (NASDAQ:LIFE)2017 EPS Consensus Estimate: ($2.08)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.49) | ($0.49) | ($0.49) |
| Q2 2017 | 1 | ($0.50) | ($0.50) | ($0.50) |
| Q3 2017 | 1 | ($0.53) | ($0.53) | ($0.53) |
| Q4 2017 | 1 | ($0.56) | ($0.56) | ($0.56) |
(Data provided by Zacks Investment Research)
Dividend History for aTyr Pharma (NASDAQ:LIFE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for aTyr Pharma (NASDAQ:LIFE)Insider Ownership Percentage: 33.30%
Institutional Ownership Percentage: 46.66%
Insider Trades by Quarter for aTyr Pharma (NASDAQ:LIFE)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/31/2017 | John Mendlein | CEO | Buy | 37,736 | $2.65 | $100,000.40 | |
| 8/31/2017 | Paul Schimmel | Director | Buy | 94,336 | $2.65 | $249,990.40 | |
| 4/24/2017 | John Mendlein | CEO | Buy | 124 | $3.00 | $372.00 | |
| 4/20/2017 | John Mendlein | CEO | Buy | 2,552 | $3.00 | $7,656.00 | |
| 12/21/2016 | Paul Schimmel | Director | Buy | 25,000 | $2.28 | $57,000.00 | |
| 12/20/2016 | Ashraf Amanullah | VP | Buy | 11,000 | $2.25 | $24,750.00 | |
| 12/19/2016 | John Mendlein | CEO | Buy | 69,000 | $2.20 | $151,800.00 | |
| 12/16/2016 | Paul Schimmel | Director | Buy | 50,000 | $2.48 | $124,000.00 | |
| 5/11/2016 | Grove Matsuoka | Insider | Buy | 12,412 | $3.04 | $37,732.48 | |
| 4/14/2016 | Paul Schimmel | Director | Buy | 66,219 | $4.18 | $276,795.42 | |
| 4/13/2016 | Paul Schimmel | Director | Buy | 9,835 | $3.85 | $37,864.75 | |
| 4/12/2016 | Paul Schimmel | Director | Buy | 9,127 | $3.71 | $33,861.17 | |
| 4/11/2016 | Paul Schimmel | Director | Buy | 32,659 | $3.57 | $116,592.63 | |
| 4/8/2016 | Paul Schimmel | Director | Buy | 85,000 | $3.22 | $273,700.00 | |
| 4/7/2016 | Paul Schimmel | Director | Buy | 40,000 | $3.19 | $127,600.00 | |
| 4/6/2016 | Paul Schimmel | Director | Buy | 25,000 | $3.20 | $80,000.00 | |
| 4/5/2016 | John Mendlein | CEO | Buy | 2,500 | $3.55 | $8,875.00 | |
| 4/5/2016 | Paul Schimmel | Director | Buy | 25,000 | $3.52 | $88,000.00 | |
| 5/12/2015 | James E Flynn | Insider | Buy | 50,000 | $14.00 | $700,000.00 | |
| 5/12/2015 | Sofinnova Venture Partners Ix, | Major Shareholder | Buy | 320,000 | $14.00 | $4,480,000.00 | |
| 5/29/2013 | David C Uprichard | Director | Sell | 2,010 | $74.04 | $148,820.40 | |
| 5/28/2013 | John A Cottingham | Insider | Sell | 60,000 | $74.03 | $4,441,800.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for aTyr Pharma (NASDAQ:LIFE)
Latest Headlines for aTyr Pharma (NASDAQ:LIFE)
| Source: |
|
| Date | Headline |
|---|
 | aTyr Pharma, Inc. (LIFE) Expected to Post Earnings of -$0.51 Per Share
www.americanbankingnews.com - October 7 at 6:26 PM |
 | How Should You Think About aTyr Pharma Inc’s (LIFE) Risks?
finance.yahoo.com - October 5 at 8:18 AM |
| aTyr Pharma, Inc. (LIFE) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - October 2 at 4:32 AM |
 | aTyr Pharma (LIFE) to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset ... - StreetInsider.com
www.streetinsider.com - September 29 at 1:58 PM |
| aTyr Pharma to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset Facioscapulohumeral Muscular Dystrophy at the 22nd International Annual Congress of the World Muscle Society
finance.yahoo.com - September 27 at 10:14 AM |
| Brokerages Expect aTyr Pharma, Inc. (LIFE) to Announce -$0.53 EPS
www.americanbankingnews.com - September 19 at 12:26 AM |
| Piper Jaffray Companies Begins Coverage on aTyr Pharma, Inc. (LIFE)
www.americanbankingnews.com - September 10 at 10:14 AM |
| aTyr Pharma to Present at Two Upcoming Investor Conferences in September
finance.yahoo.com - September 6 at 2:03 AM |
| Insider Buying: aTyr Pharma, Inc. (LIFE) CEO Buys 37,736 Shares of Stock
www.americanbankingnews.com - September 5 at 10:27 PM |
| Insider Buying: aTyr Pharma, Inc. (LIFE) Director Buys 94,336 Shares of Stock
www.americanbankingnews.com - September 5 at 10:26 PM |
| aTyr Pharma (LIFE) Reports $45M Private Placement
www.streetinsider.com - August 29 at 1:07 AM |
| aTyr Pharma Announces $45 Million Equity Financing
finance.yahoo.com - August 28 at 8:05 PM |
| [$$] Publicly Traded Rare Disease Drug-Maker aTyr Pharma Gets $46 Million Lift
finance.yahoo.com - August 28 at 8:05 PM |
| William Blair Analysts Lift Earnings Estimates for aTyr Pharma, Inc. (LIFE)
www.americanbankingnews.com - August 17 at 8:22 AM |
| aTyr Pharma, Inc. (LIFE) Releases Earnings Results, Beats Estimates By $0.06 EPS
www.americanbankingnews.com - August 15 at 2:38 PM |
| aTyr Pharma, Inc. (LIFE) Given "Hold" Rating at BMO Capital Markets
www.americanbankingnews.com - August 15 at 1:06 PM |
| aTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology Pipeline
finance.yahoo.com - August 15 at 1:02 AM |
| Atyr Pharma reports 2Q loss
finance.yahoo.com - August 15 at 1:02 AM |
| aTyr Pharma, Inc. (NASDAQ:LIFE) Expected to Announce Earnings of -$0.57 Per Share
www.americanbankingnews.com - August 13 at 2:24 AM |
| aTyr Pharma Announces Date of Earnings Release For Second Quarter 2017 Financial Results
finance.yahoo.com - August 11 at 6:08 AM |
| aTyr Pharma, Inc. (NASDAQ:LIFE) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:17 AM |
 | UPDATE 1-Contract medical research firm INC to buy inVentiv in $4.6 bln deal
www.businessinsider.com - May 11 at 11:47 PM |
 | Contract medical research firm INC to buy inVentiv in $4.6 billion deal
www.cnbc.com - May 11 at 11:47 PM |
| aTyr Pharma (LIFE) Reports Top-Line Results from Resolaris Phase 1b/2 Trial
www.streetinsider.com - April 24 at 7:23 PM |
| ATYR PHARMA INC Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - April 4 at 8:02 AM |
 | aTyr Pharma Announces Fourth Quarter and Year-End 2016 Operating Results
www.bizjournals.com - March 16 at 7:04 PM |
| ATYR PHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
us.rd.yahoo.com - March 16 at 7:04 PM |
 | aTyr Pharma (LIFE) Gains on Orphan Drug Designation
www.baystreet.ca - March 3 at 11:14 PM |
 | aTyr Pharma Receives EMA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris™
us.rd.yahoo.com - March 3 at 6:13 PM |
| 8:01 am aTyr Pharma announces that the European Medicines Agency has granted orphan drug designation to Resolaris for the treatment of limb girdle muscular dystrophy patients
us.rd.yahoo.com - March 3 at 6:13 PM |
 | BUZZ-US STOCKS ON THE MOVE-Target, Frontier, aTyr Pharma, Intelsat - Nasdaq
www.nasdaq.com - March 2 at 10:18 AM |
| aTyr Pharma (LIFE) Receives FDA Orphan Drug Designation for Treatment of LGMD with Resolaris - StreetInsider.com
www.streetinsider.com - March 2 at 10:18 AM |
 | aTyr Pharma Rises 16% on Orphan Drug Status (LIFE)
www.investopedia.com - March 1 at 5:58 PM |
| aTyr Pharma Rises 16% on Orphan Drug Status
www.investopedia.com - March 1 at 5:58 PM |
| aTyr Pharma (LIFE) Spikes on FDA Nod
www.baystreet.ca - February 28 at 6:24 PM |
| aTyr Pharma (LIFE) Receives FDA Orphan Drug Designation for Treatment of LGMD with Resolaris
www.streetinsider.com - February 28 at 6:24 PM |
| Atyr Pharma Spikes 33% on FDA Update (LIFE)
www.investopedia.com - January 20 at 1:06 AM |
| Atyr Pharma Stock Spikes 33% on FDA Updates
www.investopedia.com - January 19 at 8:04 PM |
| aTyr Pharma (LIFE) Resolaris Gains FDA Fast Track Status - StreetInsider.com
www.streetinsider.com - January 19 at 4:52 AM |
 | Gainers & Losers Of The Day: APRI, LIFE, JAZZ, ETRM, BIOC...
www.finanznachrichten.de - January 18 at 11:50 PM |
| aTyr Pharma (LIFE) Resolaris Gains FDA Fast Track Status
www.streetinsider.com - January 18 at 6:49 PM |
| FDA Grants Fast Track Designation for aTyr's Resolaris™ to Treat Limb Girdle Muscular Dystrophy 2B and Removes Partial Clinical Hold for Resolaris
us.rd.yahoo.com - January 18 at 6:49 PM |
aTyr Pharma (LIFE) Chart for Tuesday, October, 17, 2017
